LIB Therapeutics
Phase 3Developing lerodalcibep, a novel, third-generation, PCSK9 inhibitor as a convenient, single, once-monthly subcutaneous dose for patient convenience.
Founded
2015
Focus
Small Molecules
About
Developing lerodalcibep, a novel, third-generation, PCSK9 inhibitor as a convenient, single, once-monthly subcutaneous dose for patient convenience.
Funding History
2Total raised: $95M
Series B$70MOmega FundsMar 15, 2021
Series A$25MOmega FundsJun 15, 2019
Company Info
TypePrivate
Founded2015
LocationCincinnati, United States
StagePhase 3
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile